Companies ›Healthcare ›MNOV.O

MNOV.O — NASDAQ Pharmaceuticals & Medical Research

MediciNova Inc

$1,33

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

65,5M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

-3 242,4 %

ROE

-28,8 %

Net margin

-2 928,8 %

Debt / equity

0,00

Beta

—

52w range

—

Volume

136

Day range

$1,32–$1,35

Prev close

$1,33

Open

$1,32

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

MediciNova Inc is a biotechnology company focused on the development and commercialization of novel therapeutics for the treatment of inflammatory, fibrotic, and viral diseases.

Business. MediciNova Inc (MNOV.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals & Medical Research

Generated · model-assisted

Sell-side consensus

BUY4 analysts

4 buy0 hold0 sell

Avg 12m price target9,00

Analyst recommendations

4 analysts · consensus Buy

Buy4

Hold0

Sell0

12-month price target

9,00

Consensus of sell-side coverage.

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

4 analysts · indicative

Ownership→

UBS Financial Services, Inc.

largest disclosed fund holder

Profitability→

-28,8 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning MNOV.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to MNOV.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

MediciNova Inc (MNOV.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals & Medical Research

AI synthesis

GENERATED

MediciNova Inc has a strong liquidity position, with a current ratio of 8.16 and cash and equivalents amounting to $30.8 million, which significantly exceeds its total liabilities of $4.02 million. The company is debt-free, with no long-term debt, and its market capitalization of $68.9 million is supported by a price-to-book ratio of 1.66.

The company's profitability metrics are weak, with a net loss of $11.998 million and an operating loss of $13.283 million in the latest period. Return on equity (ROE) is -28.85%, and return on assets (ROA) is -26.31%, both significantly below industry norms for biotechnology firms. Gross profit of $31,050 is minimal compared to revenue of $409,660, indicating high cost structures or low pricing power.

Geographically and segment-wise, MediciNova's revenue concentration is not disclosed in the available data. The company operates in a single business segment focused on drug development, with no material geographic diversification reported. This lack of segmentation data limits visibility into potential regional risks or growth opportunities.

The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. However, the operating cash flow of -$9.81 million and free cash flow of -$11.98 million suggest ongoing operational challenges. The absence of capital expenditures beyond $2,900 indicates minimal investment in expansion or infrastructure.

Risk factors include the company's reliance on external financing to fund operations, as evidenced by its negative cash flows and lack of profitability. The risk assessment indicates low dilution potential, but the absence of long-term debt does not eliminate the need for future capital raises, which could lead to share dilution. No immediate filing-based liquidity or dilution flags were detected.

Recent events include the absence of notable filings or transcripts in the provided data. The company's financial snapshot does not reflect any recent material developments, and the analyst estimates suggest a generally positive outlook, with a mean price target of $9.00 and a median of $9.50, despite the current market price of $1.40.

Key takeaways

MediciNova Inc has a strong liquidity position with a current ratio of 8.16 and no long-term debt.
The company is currently unprofitable, with a net loss of $11.998 million and an operating loss of $13.283 million.
The company's financial snapshot does not provide detailed geographic or segment revenue data, limiting visibility into diversification.
Analysts have a generally positive outlook, with a mean price target of $9.00, but the current market price is significantly lower at $1.40.
The company's operating cash flow is negative, indicating ongoing operational challenges and a need for external financing.
**margin_outlook_rationale**: The company's gross profit margin is extremely low, indicating significant cost pressures or pricing challenges.
**rd_outlook_rationale**: No specific R&D outlook is provided in the available data.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$1,33

Market cap

$68.9M

Enterprise valueⓘ

$38.1M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

1.7x

P / Tangible bookⓘ

1.7x

Tangible book

$41.6M

Net cashⓘ

$30.8M

Current ratioⓘ

8.2

Debt / equityⓘ

0.0

ROAⓘ

-26.3%

ROEⓘ

-28.8%

Cash conversionⓘ

82.0%

CapEx / revenueⓘ

-0.7%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs MNOV · multiples and returns

KLAR—

KLAR.ST

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

BNTX—

Biontech SE

$92,25

23,3B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

EXEL—

Exelixis Inc

$55,06

14,7B USD

P/E

19,5x

— vs self

Div yield

—

— vs self

ROE

40,4 %

+69,3 vs self

MDGL—

Madrigal Pharmaceuticals Inc

$482,00

11,0B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-47,8 %

-19,0 vs self

INSM—

Insmed Inc

$107,46

23,0B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-160,2 %

-131,3 vs self

VCYT—

Veracyte Inc

$45,30

3,6B USD

P/E

55,5x

— vs self

Div yield

—

— vs self

ROE

5,1 %

+33,9 vs self

MDXG—

Mimedx Group Inc

$4,27

636,0M USD

P/E

11,1x

— vs self

Div yield

—

— vs self

ROE

18,9 %

+47,8 vs self

AVIR—

Atea Pharmaceuticals Inc

$4,61

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

-57,5 %

-28,6 vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,30

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-16 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,30
Revenue	—no estimate	—no estimate	125,000 USD
Operating income	—no estimate	—no estimate	-23,3M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution4 analysts

Strong buy0

Buy4

Hold0

Sell0

Strong sell0

12-month price target$9,00 · Median $9,50

Low $6,00High $11,00

Operating income · consensus-23,3M USD

EPS surprise

+21,3 %

reported vs consensus · beat

Revenue surprise

+227,2 %

reported vs consensus · beat

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$6,00

Mean$9,00

Median$9,50

High$11,00

Spot$1,33

+576.7 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin-3 242,4 %Bottom quartile

Net Margin-2 928,8 %Bottom quartile

ROE-28,8 %Above median

Capex / Rev-0,7 %Above median

D/E0,00Above median

Cash Conv0,82Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 933 500 sh5 grants5 insiders

Lemerond NicoleDirector · Stock Option (Right to Buy) → Common StockAcquired 44 500 @ $1,36grant · 2026-06-23
BEAVER CAROLYNDirector · Stock Option (Right to Buy) → Common StockAcquired 44 500 @ $1,36grant · 2026-06-23
Nagao HidekiDirector · Stock Option (Right to Buy) → Common StockAcquired 44 500 @ $1,36grant · 2026-06-23
Matsuda KazukoChief Medical Officer · Employee Stock Option (Right to Buy) → Common StockAcquired 350 000 @ $2,10grant · 2026-01-16
IWAKI YUICHIPresident and CEO · Employee Stock Option (Right to Buy) → Common StockAcquired 450 000 @ $2,10grant · 2026-01-16

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Return On Equity
net_income / total_equity
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted
Ev To Revenue
enterprise_value / revenue

Source documents

MediciNova Inc Market data — financials · 2026-05-28
MediciNova Inc Market data — analyst estimates · 2026-05-28
MediciNova Inc Market data — ESG · 2026-05-28

Ownership & reference

Top holders

UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$1M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$1M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$0M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$0M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$1M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M

Insider activity

— missing data

Short positioning

310.4Kshares short+51.5% vs prior

4.26days to cover

22.4%short of daily vol

1.0Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

MNOV.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

Net margin (FY 2025-12-31): 2,928.8%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -4.3%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -4.3%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 19.1%Derived (calculated)
Return on equity (FY 2025-12-31): 28.9%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): -18.4%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -20.8%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): -1.5%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): -4.8%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 7.8%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): 8.6%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -23.7%Derived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): 223.9%Derived (calculated)
Debt-to-equity (FY 2025-12-31): 0.10xDerived (calculated)
Current ratio (FY 2025-12-31): 8.16xDerived (calculated)
Return on assets (FY 2025-12-31): 26.3%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2023-12-31): -59.0%Derived (calculated)
EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
R&D expense (annual): USD 6.7MSEC XBRL filing
Operating income (annual): USD -13.28MSEC XBRL filing
Operating cash flow (annual): USD -9.81MSEC XBRL filing
Total liabilities (annual): USD 4.02MSEC XBRL filing
Cash & equivalents (annual): USD 30.81MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-23 00:00 UTCINSIDER3 insider transactions — 2026-06 3 derivative

2026-06-23INSIDERLemerond Nicole acquired 44.5k sh Stock Option (Right to Buy) — Director

2026-06-23INSIDERNagao Hideki acquired 44.5k sh Stock Option (Right to Buy) — Director

2026-06-23INSIDERBEAVER CAROLYN acquired 44.5k sh Stock Option (Right to Buy) — Director

2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated

2026-05-14FILING10-Q filing →

2026-04-29FILINGDEF 14A filing →

2026-03-10FILING10-K filing →

2026-02-20FILING8-K filing →

2026-01-16 00:00 UTCINSIDER2 insider transactions — 2026-01 2 derivative

2026-01-16INSIDERIWAKI YUICHI acquired 450.0k sh Employee Stock Option (Right to Buy) — President and CEO

2026-01-16INSIDERMatsuda Kazuko acquired 350.0k sh Employee Stock Option (Right to Buy) — Chief Medical Officer

2025-12-30FILING424B5 filing →

2025-12-30FILING8-K filing →

2025-11-12FILING10-Q filing →

2025-08-22FILINGS-1 filing →

2025-08-14FILING10-Q filing →

2025-08-01FILING8-K filing →

2025-06-18FILING8-K filing →

2025-06-17 00:00 UTCINSIDER3 insider transactions — 2025-06 3 derivative

2025-05-13FILING10-Q filing →

2025-02-12 00:00 UTCINSIDER5 insider transactions — 2025-02 5 derivative

2025-01-07 00:00 UTCINSIDER2 insider transactions — 2025-01 2 derivative

2024-06-11 00:00 UTCINSIDER3 insider transactions — 2024-06 3 derivative

2024-01-09 00:00 UTCINSIDER3 insider transactions — 2024-01 3 derivative

2023-08-04 00:00 UTCINSIDER1 insider transaction — 2023-08 1 derivative

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread